Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
ConditionGram-negative Bacteremia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorJohns Hopkins University
About this trial
The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is as effective but safer than remaining on intravenous (IV) antibiotic therapy for the duration of treatment.
Eligibility criteria
Qualifiers
Adult (≥ 18 years) at the time of screening
Hospitalized
Identification of at least one Gram-negative organism in a blood culture
Capable of providing written informed consent (includes through a legally authorized representative)
Disqualifiers
Unable to tolerate or absorb a course of oral antibiotics
Actively receiving vasopressors
Gram-negative organism not susceptible to any oral antibiotics
Gram-negative organism not susceptible to any IV antibiotics
Trial design
Treatments tested in this trial
- Intravenous Antibiotics
- Oral Antibiotics
Treatment groups
1,030 Participants
are divided into 2 treatment groupsLocations
11California
University of California, San Francisco94143, San Francisco United States
Colorado
Denver Health Hospital Authority80204, Denver United States
Maryland
Johns Hopkins University Hospital Systems21287, Baltimore United States
University of Maryland Medical Center21202, Baltimore United States
Sponsors and collaborators
Johns Hopkins University
Lead sponsor
Patient-Centered Outcomes Research Institute
Collaborator
Source ClinicalTrials.gov